Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs

Hirokazu Tamamura; Hiroshi Tsutsumi; Hiroyuki Masuno; Satoko Mizokami; Kenichi Hiramatsu; Zixuan Wang; John O Trent; Hideki Nakashima; Naoki Yamamoto; Stephen C Peiper; Nobutaka Fujii

doi:10.1039/b603818b

Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs

Org Biomol Chem. 2006 Jun 21;4(12):2354-7. doi: 10.1039/b603818b. Epub 2006 May 12.

Authors

Hirokazu Tamamura¹, Hiroshi Tsutsumi, Hiroyuki Masuno, Satoko Mizokami, Kenichi Hiramatsu, Zixuan Wang, John O Trent, Hideki Nakashima, Naoki Yamamoto, Stephen C Peiper, Nobutaka Fujii

Affiliation

¹ Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Japan. tamamura.mr@tmd.ac.jp

PMID: 16763678
DOI: 10.1039/b603818b

Abstract

A linear type of several low molecular weight CXCR4 antagonists were developed based on T140 analogs, which were previously found to be strong CXCR4 antagonists that block X4-HIV-1 entry and have inhibitory activities against cancer metastasis/progression and rheumatoid arthritis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / chemical synthesis
Anti-HIV Agents / chemistry
Anti-HIV Agents / pharmacology
Antineoplastic Agents / chemical synthesis
Antineoplastic Agents / chemistry
Antineoplastic Agents / pharmacology
Cell Line
Humans
Molecular Weight
Oligopeptides / chemistry*
Oligopeptides / pharmacology*
Peptides, Cyclic / chemical synthesis
Peptides, Cyclic / chemistry
Peptides, Cyclic / pharmacology
Receptors, CXCR4 / antagonists & inhibitors*

Substances

Anti-HIV Agents
Antineoplastic Agents
Oligopeptides
Peptides, Cyclic
Receptors, CXCR4
T140 peptide